Skip to content

AI-driven initiative aimed at creating a surveillance system for tracking advancement of musculoskeletal conditions

Artificial Intelligence-driven system devised by AIMPLAS and partners is aimed at tracking and assessing advancement of musculoskeletal diseases.

AI-driven initiative aims to create a system that tracks the progression of musculoskeletal...
AI-driven initiative aims to create a system that tracks the progression of musculoskeletal diseases

AI-driven initiative aimed at creating a surveillance system for tracking advancement of musculoskeletal conditions

In the ever-evolving world of healthcare, the latest advancements are making a significant impact on the treatment of musculoskeletal disorders. Two key areas of focus are AI-powered solutions and portable monitoring systems, both of which are set to transform the way we approach these common conditions.

On the AI front, platforms like RevelAi Health are leading the charge. This innovative system acts as a 24/7 virtual care navigator for orthopedic practices, automating tasks such as evidence-based triage and converting encounters into structured clinical notes. By aligning with CMS' episode accountability models, RevelAi Health supports the shift towards value-based care.

AI is also playing a crucial role in rehabilitation, particularly in the prediction of patient expectations and assumptions. Artificial mental models (AMMs) can optimize treatment decisions in musculoskeletal rehabilitation, addressing cognitive limitations and misjudgments.

Portable monitoring systems are another game-changer. The SMART-US wearable ultrasound + AI device, developed by George Mason University, is designed for muscle function assessment. This device uses distributed M-mode ultrasound sensors and AI to predict muscle force with high accuracy, providing real-time data on muscle dynamics during activities like isometric squats.

While specific non-surgical treatments for Arthrogenic Muscle Inhibition (AMI) were not detailed in the search results, AI can still play a pivotal role in managing and treating musculoskeletal conditions by enhancing diagnostic accuracy and providing personalized care plans. Traditional non-surgical approaches to AMI often include physical therapy, rehabilitation exercises, and pain management strategies, which can be supported and optimized by AI-driven insights.

Looking to the future, the integration of AI in personalized rehabilitation could tailor programs for conditions like AMI by analysing patient data and predicting recovery trajectories. Advanced monitoring systems like SMART-US could revolutionize how muscle function is assessed during rehabilitation, potentially offering insights into AMI treatment efficacy.

A prime example of this is the KINESSENSOR project, which aims to develop an AI-powered, portable system for identifying, monitoring, and tracking joint, ligament, or muscle injuries or pain. This project aligns with Sustainable Development Goals 3, 8, and 9, contributing to more personalised, efficient, and accessible medicine.

The KINESSENSOR project has potential for a spin-off due to its novelty and high application potential. It involves developing a data analysis system with wireless communication and real-time monitoring, and the incorporation of AI is intended to identify patterns that allow healthcare professionals to correct them immediately.

The use of the KINESSENSOR system improves rehabilitation outcomes, reduces costs, and recovery time. The project specifically targets a condition called arthrogenic muscle inhibition (AMI), which causes hypertonia in the hamstring muscles and is common in anterior cruciate ligament injuries and knee prosthetic surgery.

The World Health Organization reports that musculoskeletal disorders, including osteoarthritis, arthritis, and sports injuries, affect over 1.7 billion people worldwide. The KINESSENSOR system allows patients to perform exercises and treatments at home while being monitored, a significant step towards making healthcare more accessible.

The KINESSENSOR project is funded by the Valencian Institute of Competitiveness and Innovation (IVACE+i) through the 2024 Strategic Cooperation Projects program and the European Regional Development Fund (ERDF). It is a clear example of how applied research and technological innovation can directly improve people's quality of life.

The project has been launched by a consortium consisting of Blautic Designs, AIMPLAS, IMSKE, Crespo Printing Group, and UPV, demonstrating the collaborative effort required to drive such transformative changes in healthcare.

In the realms of digital health, AI is being utilized to revolutionize the rehabilitation process for musculoskeletal conditions, such as Arthrogenic Muscle Inhibition (AMI). Innovative systems like RevelAi Health and KINESSENSOR are transforming healthcare, with RevelAi Health providing automated triage and structure notes, aligning with CMS' episode accountability models. The KINESSENSOR project, on the other hand, aims to develop a portable, AI-powered system to identify, monitor, and track joint, ligament, or muscle injuries or pain, making musculoskeletal rehabilitation more accessible for chronic-kidney-disease patients and those with chronic-diseases worldwide. This project contributes to health-and-wellness goals by offering personalized therapies-and-treatments and promoting value-based care.

Read also:

    Latest

    Pharmaceutical titans such as J&J and Merck are positioned for a critical juncture, as they prepare...

    Drug giants, such as J&J and Merck, confront a critical juncture as they prepare for substantial income drops upon the expiration of patents for their high-earning medications.

    Overcome hurdles in the pharmaceutical sector's patent expiration periods, learning about key entities such as Bristol Myers Squibb, Merck, and Johnson & Johnson. Glean intel on techniques used to tackle revenue hazards, encompassing the creation of sturdy drug pipelines and strategic buyouts....